Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners. (December 2022)

• Record Type: Journal Article
• Authors: Chazan, Grace; Jupp, Jennifer; Bauters, Tiene; Duncan, Nick; Weddle, Kellie Jones; Nomura, Hisanaga; O'Connor, Shaun; Chan, Alexandre; Alkhudair, Nora; Alshamrani, Majed; Buie, Larry W; Chambers, Pinkie; Chieh, Tan Wen; DeRemer, David L; Duvivier, France; Katabalo, Deogratias; McFarlane, Thomas; Mckavanagh, Daniel; Mensah, Kofi; Martinez, Estela Moreno; Rowan, Gail; Sae-teaw, Manit; Tadesse, Tamrat Assefa; Weru, Irene; Alexander, Marliese
• Is Part Of: Journal of oncology pharmacy practice. Volume 28:Number 8(2022)
• Page Start: 1832
• Page End: 1847
• Publication Date: 2022-12
• Subjects: Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/10781552211048892
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: The coronavirus of 2019 pandemic has necessitated vast and rapid changes in the way oncology pharmacy services are delivered around the world. Methods/aims: An international survey of oncology pharmacists and technicians was conducted via the International Society of Oncology Pharmacy Practitioners and collaborating global pharmacy organisations to determine the impact that the coronavirus of 2019 has had on pharmacy service delivery, pharmacy practitioners and oncology practice. Results: The survey received 862 responses from 40 different countries from September to October 2020. The majority of respondents were pharmacists ( n = 841, 97.6%), with 24% involved in the direct care of patients with the coronavirus of 2019. Of the survey participants, 55% increased their time working remotely, with remote activities including dispensing, patient assessment/follow-up and attending multi-disciplinary rounds. Respondents reported a 72% increase in the use of technology to perform remote patient interaction activities and that participation in educational meetings and quality improvement projects was reduced by 68% and 44%, respectively. Workforce impacts included altered working hours (50%), cancelled leave (48%) and forced leave/furloughing (30%). During the pandemic, respondents reported reduced access to intensive care (19%) and anti-cancer (15%) medications. In addition, 39% of respondents reported reduced access to personal protective equipment, including N95 masks for chemotherapy compounding. Almost half of respondents (49%) reported that cancer treatments were delayed or intervals were altered for patients being treated with curative intent. A third of practitioners (30%) believed that patient outcomes would be adversely impacted by changes to pharmacy services. Sixty-five percent of respondents reported impacts on their mental health, with 12% utilising support services. Conclusion: The coronavirus of 2019 pandemic has altered the way oncology pharmacy services are delivered. These results demonstrate the adaptability of the oncology pharmacy profession and highlight the importance of formal evaluation of the varied practice models to determine the evidence-based practices that enhance pharmacy services and, thus, should be reinstated as soon as practical and reasonable.